The Role of Adjuvant Radiotherapy for Early‐Stage Oral Cavity Cancer With Minor Adverse Features; A Single Institute Experience
Head & Neck · 2025
DOI: 10.1002/hed.28093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Eyal Yosefof und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Tongue Neoplasms, Mouth Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The role of post‐operative radiotherapy (PORT) in early‐stage (T1‐T2N0M0) oral tongue squamous cell carcinoma (OTSCC) with minor adverse features (MAF) including perineural invasion (PNI) and poorly differentiated carcinoma (PDC) is not well described. We aimed to study the role of PORT among these patients.
Methods
A retrospective review of patients treated for early‐stage OTSCC between 2000 and 2022 in a tertiary‐care referral center while comparing patients treated by surgery and PORT with patients treated by surgery alone.
Results
One hundred fifty‐four patients were included and 36 (23.4%) received PORT. The PORT subgroup had a significantly higher rate of MAF. Survival rates were similar between the two sub‐groups. PORT demonstrated a trend toward improved overall survival (odds ratio = 0.406, p = 0.07). Patients with PNI or PDC treated with PORT experienced improved survival rates.
Conclusion
PORT has an important role when treating early‐stage OTSCC with MAF. It should be considered especially among patients with PNI or PDC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology Head and Neck Surgery, Rabin Medical Center, Petah Tikva, Israel.
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
ORCID-Profile: Eyal Yosefof, Nofar Edri
Zitieren
APA
Yosefof, E., Edri, N., Kurman, N., Bachar, G., Shpitzer, T., Mizrachi, A., & Popovtzer, A. (2025). The Role of Adjuvant Radiotherapy for Early‐Stage Oral Cavity Cancer With Minor Adverse Features; A Single Institute Experience. Head & Neck. https://doi.org/10.1002/hed.28093
Vancouver
Yosefof E, Edri N, Kurman N, Bachar G, Shpitzer T, Mizrachi A, et al. The Role of Adjuvant Radiotherapy for Early‐Stage Oral Cavity Cancer With Minor Adverse Features; A Single Institute Experience. Head & Neck. 2025. doi:10.1002/hed.28093
BibTeX
@article{Yosefof2025,
author = {Yosefof, Eyal and Edri, Nofar and Kurman, Noga and Bachar, Gideon and Shpitzer, Thomas and Mizrachi, Aviram and Popovtzer, Aron},
title = {The Role of Adjuvant Radiotherapy for Early‐Stage Oral Cavity Cancer With Minor Adverse Features; A Single Institute Experience},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.28093}
}
EUVIMED